283 related articles for article (PubMed ID: 16464483)
1. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.
Nong A; McCarver DG; Hines RN; Krishnan K
Toxicol Appl Pharmacol; 2006 Jul; 214(1):78-87. PubMed ID: 16464483
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the impact of the exposure route on the human kinetic adjustment factor.
Valcke M; Krishnan K
Regul Toxicol Pharmacol; 2011 Mar; 59(2):258-69. PubMed ID: 20969910
[TBL] [Abstract][Full Text] [Related]
3. An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants.
Valcke M; Krishnan K
Toxicology; 2011 Aug; 286(1-3):36-47. PubMed ID: 21605617
[TBL] [Abstract][Full Text] [Related]
4. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
Pelekis M; Gephart LA; Lerman SE
Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans.
Tardif R; Charest-Tardif G; Brodeur J; Krishnan K
Toxicol Appl Pharmacol; 1997 May; 144(1):120-34. PubMed ID: 9169076
[TBL] [Abstract][Full Text] [Related]
6. The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform.
Lipscomb JC; Barton HA; Tornero-Velez R; Evans MV; Alcasey S; Snawder JE; Laskey J
J Toxicol Environ Health A; 2004 Apr; 67(7):537-53. PubMed ID: 15129551
[TBL] [Abstract][Full Text] [Related]
7. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children.
Price K; Haddad S; Krishnan K
J Toxicol Environ Health A; 2003 Mar; 66(5):417-33. PubMed ID: 12712630
[TBL] [Abstract][Full Text] [Related]
8. Modeling the toxicokinetics of inhaled toluene in rats: influence of physical activity and feeding status.
Kenyon EM; Benignus V; Eklund C; Highfill JW; Oshiro WM; Samsam TE; Bushnell PJ
J Toxicol Environ Health A; 2008; 71(4):249-65. PubMed ID: 18253891
[TBL] [Abstract][Full Text] [Related]
9. Assessing the impact of the duration and intensity of inhalation exposure on the magnitude of the variability of internal dose metrics in children and adults.
Valcke M; Krishnan K
Inhal Toxicol; 2011 Dec; 23(14):863-77. PubMed ID: 22084919
[TBL] [Abstract][Full Text] [Related]
10. Elevated internal exposure of children in simulated acute inhalation of volatile organic compounds: effects of concentration and duration.
Abraham K; Mielke H; Huisinga W; Gundert-Remy U
Arch Toxicol; 2005 Feb; 79(2):63-73. PubMed ID: 15565428
[TBL] [Abstract][Full Text] [Related]
11. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
12. A dosimetric analysis of the acute behavioral effects of inhaled toluene in rats.
Bushnell PJ; Oshiro WM; Samsam TE; Benignus VA; Krantz QT; Kenyon EM
Toxicol Sci; 2007 Sep; 99(1):181-9. PubMed ID: 17548890
[TBL] [Abstract][Full Text] [Related]
13. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants.
Ginsberg G; Hattis D; Sonawane B
Toxicol Appl Pharmacol; 2004 Jul; 198(2):164-83. PubMed ID: 15236952
[TBL] [Abstract][Full Text] [Related]
14. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics.
Yoon M; Madden MC; Barton HA
J Toxicol Environ Health A; 2007 Sep; 70(18):1527-41. PubMed ID: 17710613
[TBL] [Abstract][Full Text] [Related]
15. Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants.
Valcke M; Krishnan K
Regul Toxicol Pharmacol; 2013 Feb; 65(1):126-34. PubMed ID: 23200794
[TBL] [Abstract][Full Text] [Related]
16. Human hepatic CYP2E1 expression during development.
Johnsrud EK; Koukouritaki SB; Divakaran K; Brunengraber LL; Hines RN; McCarver DG
J Pharmacol Exp Ther; 2003 Oct; 307(1):402-7. PubMed ID: 14500779
[TBL] [Abstract][Full Text] [Related]
17. Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.
Valcke M; Haddad S
J Toxicol Environ Health A; 2015; 78(7):409-31. PubMed ID: 25785556
[TBL] [Abstract][Full Text] [Related]
18. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Kirman CR; Sweeney LM; Corley R; Gargas ML
Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
[TBL] [Abstract][Full Text] [Related]
19. Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals.
Béliveau M; Lipscomb J; Tardif R; Krishnan K
Chem Res Toxicol; 2005 Mar; 18(3):475-85. PubMed ID: 15777087
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of human cytochrome P4502E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells.
Hanioka N; Yamamoto M; Tanaka-Kagawa T; Jinno H; Narimatsu S
Arch Toxicol; 2010 May; 84(5):363-71. PubMed ID: 20033806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
